Mission and Vision Statement
Aurobindo pharma ltd mission is to become the World Pharma Biggest valuable pharma partner by continually researching, developing and producing comprehensive pharmaceutical products that comply with the highest regulatory standards.
Business overview
Shri P.V. Founded in 1986. Ramprasad Reddy, Shri. K Nitinand Reddy and a small group of highly committed professionals, Aurobindo Pharma was born with a vision. The company started a single unit producing semi-synthetic penicillin (SSP) at Pondicherry in 198 88-in.
Aurobindo Pharma became a public company and 1995 1995 listed its shares in the Indian stock market in 1995. Apart from being a leader in the market for semi-synthetic penicillins, Aurobindo Pharma has a presence in the main therapeutic divisions of neuroscience (CNS), cardiovascular and blood vessels. (CVS), anti-retroviral, anti-diabetic, gastroenterology and antibiotics
Through its cost-effective production capabilities and some loyal customers, the company entered the high margin specialty generic formulation division. Today, Aurobindo Pharma has evolved as a knowledge-driven company producing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in many countries.
The formulation business is organized systematically with a departmental structure and is the focus team for the international market. Using APIs and formulations, a wide variety of basket products, and large production infrastructure for customer confidence, Aurobindo generated $ 6.6 billion in Fiscal Year 7-8-18. API / Intermediates for Formulation and 11 units of Aurobindo (10 in India, 3 in the USA, 1 in Brazil and 1 in Portugal) are designed to meet the needs of both advanced and emerging market opportunities.
In terms of consolidated revenue, Aurobindo Pharma is a good company and is among the first two pharmaceutical companies in India. Aurobindo exports to more than 150 countries worldwide with around 90% of its revenues from international operations. Our clients include premium multi-national companies. Medicines Master Files (DMF) uses Aurobindo In-House R&D to expedite patents, with many facilities approved by leading regulatory agencies such as the USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada, WHO and Brazil Anvisa. ), Abbreviated New Drug Applications (ANDA) and formulation dossiers around the world. Aurobindo Pharma is one of DMF and ANDA's largest filers.
Formulation
Overview
Aurobindo Pharma Limited is a vertically integrated pharmaceutical company that offers innovative solutions. From discovery to development to commercialization, our growth is supported by low cost drug development and mass production.
Taking advantage of India's globally competitive cost base and talented team of scientists, we have successfully launched affordable products available worldwide.
Production capacity
Aurobindo has maintained the same drive for growth that marked its early days. Starting in 1988 with the launch of a small SSP manufacturing unit, Aurobindo became the market leader in SSPs, non-penicillins, cephalosporins and non-cephalosporins. In the global marketplace, we believe in maintaining our leadership in SSPs, cephalosporins, new anti-infectives and lifestyle disease drugs.
We want:
Increase territory expansion, partnerships, globalization and lucrative markets through joint ventures and further access by subsidiaries.
Develop a comprehensive portfolio of products through non-infringing processes and be a key player in the field of generics.
Emerging as a leading global player in high quality, innovative specialty generic formulations
Production capacity
Aurobindo has maintained the same drive for growth that marked its early days. Starting in 1988 with the launch of a small SSP manufacturing unit, Aurobindo became the market leader in SSPs, non-penicillins, cephalosporins and non-cephalosporins. In the global marketplace, we believe in maintaining our leadership in SSPs, cephalosporins, new anti-infectives and lifestyle disease drugs.
